Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06028373 · ClinicalTrials.gov registry record · Phase 1

A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

A Phase 1 study of Advanced Solid Tumors and B-cell Non-Hodgkin Lymphomas, sponsored by Antengene Biologics Limited.

Recruiting
Registry status
Phase 1
Development phase
80
Enrollment target
4
Study locations

NCT06028373 is a Phase 1 study of Advanced Solid Tumors and B-cell Non-Hodgkin Lymphomas that is actively recruiting participants, run by Antengene Biologics Limited. The registered enrollment target is 80 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (60% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06028373, a Phase 1 study of Advanced Solid Tumors and B-cell Non-Hodgkin Lymphomas, is actively recruiting participants, sponsored by Antengene Biologics Limited.

RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
4
Study locations

Study Summary

ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced solid tumors (i.e., preferred tumor types) or relapsed/refractory (R/R) B-NHLs. The study's primary objective is to evaluate the safety and tolerability of ATG-031 and determine the RP2D（Refered Phase II dose） of ATG-031.

Conditions Studied

Advanced Solid Tumors B-cell Non-Hodgkin Lymphomas

Interventions

  • DRUG ATG-031

Study Locations (4)

California

  • University of California San Francisco (UCSF) - San Francisco

Colorado

  • Regents of the University of Colorado - Aurora

Connecticut

  • Yale University - New Haven

Texas

  • University of Texas M.D. Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2023-12-08
Est. Completion 2027-06-30
Phase Phase 1

Sponsor

Antengene Biologics Limited

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06028373

The ClinicalTrials.gov registry entry for NCT06028373 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (60% lower). The listed sponsor is Antengene Biologics Limited, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which ATG-031 is the first listed.

NCT06028373 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06028373 about?

NCT06028373 is a clinical study titled "A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas". ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced solid tumors (i.e., preferred tumor types) or re...

What is the current status of trial NCT06028373?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2023-12-08. Estimated completion is 2027-06-30.

What conditions does trial NCT06028373 study?

This clinical trial studies the following conditions: Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas.

What interventions are being tested in trial NCT06028373?

The interventions under investigation include: ATG-031 (DRUG).

Who is sponsoring clinical trial NCT06028373?

This trial is sponsored by Antengene Biologics Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06028373 being conducted?

This trial has 4 study locations across California, Colorado, Connecticut, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

B-cell Non-Hodgkin Lymphomas

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.